Rayner Pharmaceuticals Issues Class 4 Medicines Defect Notification for Dropodex Eye Drops
Rayner Pharmaceuticals has notified the MHRA of a defect in Dropodex 0.1% w/v Eye Drops due to missing phosphate concentration information.
Asset / Drug
Drug and asset intelligence for Rayner with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.